Cookies on this website

We use cookies to improve your experience of our website. You can find out more or opt-out from some cookies.

Skip to content
Healthcare Improvement Scotland
  • Clinical guidance
  • Improving care
  • Inspections and reviews
  • News
  • Publications
  • Work with us
    1. Home
    2. Process guidance
    3. NCMAG advice
    4. NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    Back to   Home

    NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    Posted on: 26 October 2023


    Document Type

    NCMAG advice

    Process guidance

    Summary

    Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options. (Off-label use)

    Decision: supported


    Documents

    NCMAG107 Dabrafenib plus trametinib advice document: October 2023

    PDF, 1MB

    Posted in NCMAG advice, Process guidance

    Footer Navigation

    • About us
    • Contact us
    • Media Centre
    • Podcasts
    • Events
    • How we use cookies
    • Our privacy policy
    • Accessibility statement
    • Copyright information
    • Complaints and feedback
    Footer Logo

    © 2026 Healthcare Improvement Scotland


    Social Media Links

    Follow Healthcare Improvement Scotland
    • Follow us on Bluesky Follow us on Bluesky (opens in new tab)
    • Follow us on Facebook Follow us on Facebook (opens in new tab)
    • Follow us on X Follow us on X (opens in new tab)
    • Follow us on YoutTube Follow us on YoutTube (opens in new tab)
    • Follow us on LinkedIn Follow us on LinkedIn (opens in new tab)